News
SDGR
14.15
-2.55%
-0.37
Schrödinger Finalizes Transition Terms for Former Commercial Chief
TipRanks · 2d ago
Schrodinger confirms separation of Chief Commercial Officer Mannix Aklian
PUBT · 2d ago
Weekly Report: what happened at SDGR last week (0601-0605)?
Weekly Report · 2d ago
Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026?
The Motley Fool · 06/02 21:32
Does Schrödinger (SDGR) Changing Its CCO While Reaffirming Guidance Recast Its Commercial Playbook?
Simply Wall St · 06/02 05:16
Weekly Report: what happened at SDGR last week (0525-0529)?
Weekly Report · 06/01 09:46
Private Markets: Cognition AI raises $1B, Modal secures $355M
TipRanks · 05/28 17:37
Weekly Report: what happened at SDGR last week (0518-0522)?
Weekly Report · 05/25 09:48
Schrodinger grants inducement equity awards totaling 20,641 shares to new hires
PUBT · 05/22 12:30
SCHRÖDINGER REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 05/22 12:30
Analysts Are Bullish on These Healthcare Stocks: Personalis (PSNL), Eton Pharmaceuticals (ETON)
TipRanks · 05/21 16:50
Schrödinger Announces Leadership Change Amid Maintained 2026 Outlook
TipRanks · 05/20 21:49
Schrodinger Reaffirms FY And Q2 2026 Financial And Operational Guidance
Benzinga · 05/20 21:00
SCHRODINGER INC - REAFFIRMS FULL-YEAR AND Q2 2026 FINANCIAL AND OPERATIONAL GUIDANCE - SEC FILING
Reuters · 05/20 20:58
Schrodinger names Paul Davie interim chief commercial officer after Mannix Aklian exit
PUBT · 05/20 20:20
My Top 3 Biotech Stocks for May 2026
The Motley Fool · 05/20 15:35
Schrödinger Balances Growth and Losses in Earnings Call
TipRanks · 05/20 07:55
Weekly Report: what happened at SDGR last week (0511-0515)?
Weekly Report · 05/18 09:47
Private Markets: $2.1B for Isomorphic Labs, massive raise looming for Anthropic
TipRanks · 05/14 20:23
Schrodinger Price Target Cut to $17.00/Share From $19.00 by Morgan Stanley
Dow Jones · 05/14 17:35
More
Webull provides a variety of real-time SDGR stock news. You can receive the latest news about Schrodinger, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About SDGR
Schrodinger, Inc. is a developer of a physics-based computational platform that enables discovery of molecules for drug development and materials applications. The Company's segments include Software and Drug Discovery. The Software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in the material science industries. The Drug Discovery segment is focused on building a portfolio of preclinical and clinical drug programs, internally and through collaborations. It offers WaterMap, which characterizes the locations and energetics of water molecules occupying the binding site of, or solvating, a target protein. It also offers FEP+, which is a free energy calculation software which can be used to replace the central core of earlier known tight binding molecules to identify potent molecules unavailable in library collections. It can also be used to calculate absolute binding affinities.